These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 10592921

  • 21. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
    Cavallo L, Gurrado R, Zecchino C, Manolo F, De Sanctis V, Cisternino M, Caruso-Nicoletti M, Galati M.
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():845-9. PubMed ID: 10091155
    [Abstract] [Full Text] [Related]

  • 22. [The mechanism of cataract formation in persons with beta-thalassemia].
    Popescu C, Siganos D, Zanakis E, Padakis A.
    Oftalmologia; 1998; 45(4):10-3. PubMed ID: 10418622
    [Abstract] [Full Text] [Related]

  • 23. Short stature and body proportion in thalassaemia.
    Caruso-Nicoletti M, De Sanctis V, Capra M, Cardinale G, Cuccia L, Di Gregorio F, Filosa A, Galati MC, Lauriola A, Malizia R, Mangiagli A, Massolo F, Mastrangelo C, Meo A, Messina MF, Ponzi G, Raiola G, Ruggiero L, Tamborino G, Saviano A.
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():811-6. PubMed ID: 10091151
    [Abstract] [Full Text] [Related]

  • 24. Malignancies in patients with beta-thalassemia major and beta-thalassemia intermedia: a multicenter study in Iran.
    Karimi M, Giti R, Haghpanah S, Azarkeivan A, Hoofar H, Eslami M.
    Pediatr Blood Cancer; 2009 Dec; 53(6):1064-7. PubMed ID: 19533641
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Thyroid function in thalassaemia major.
    Senanayake MP, Suraweera SA, Hubert HD.
    Ceylon Med J; 1999 Dec; 44(4):166-8. PubMed ID: 10895267
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
    Tamary H, Goshen J, Carmi D, Yaniv I, Kaplinsky C, Cohen IJ, Zaizov R.
    Isr J Med Sci; 1994 Aug; 30(8):658-64. PubMed ID: 8045754
    [Abstract] [Full Text] [Related]

  • 30. Survival and complications in thalassemia.
    Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A.
    Ann N Y Acad Sci; 2005 Aug; 1054():40-7. PubMed ID: 16339650
    [Abstract] [Full Text] [Related]

  • 31. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP, Kumar S, Choudhury P, Talukdar B, Puri RK.
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [Abstract] [Full Text] [Related]

  • 32. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF).
    De Sanctis V, Eleftheriou A, Malaventura C, Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia.
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():249-55. PubMed ID: 16462705
    [Abstract] [Full Text] [Related]

  • 33. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A, Imbach P, Pfenninger E, Stocker F, Töndury P, Wagner HP, Weber J, Zuppinger K.
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [Abstract] [Full Text] [Related]

  • 34. Survival in medically treated patients with homozygous beta-thalassemia.
    Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR.
    N Engl J Med; 1994 Sep 01; 331(9):574-8. PubMed ID: 8047081
    [Abstract] [Full Text] [Related]

  • 35. Beta thalassemia major: the effect of age on glomerular filtration rate.
    Malaki M, Sorkhabi RS, Shoaran M, Shafighe B.
    Saudi J Kidney Dis Transpl; 2011 Sep 01; 22(5):963-8. PubMed ID: 21912026
    [Abstract] [Full Text] [Related]

  • 36. [Guidelines for diagnosis and treatment of secondary iron overload in patients with congenital anemia].
    Cario H, Grosse R, Janssen G, Jarisch A, Meerpohl J, Strauss G, German hematology societies (GPOH and DGHO).
    Klin Padiatr; 2010 Nov 01; 222(6):399-406. PubMed ID: 20862634
    [Abstract] [Full Text] [Related]

  • 37. [Psychosocial aspects of beta-thalassemia: distress, coping and adherence].
    Goldbeck L, Baving A, Kohne E.
    Klin Padiatr; 2000 Nov 01; 212(5):254-9. PubMed ID: 11048284
    [Abstract] [Full Text] [Related]

  • 38. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
    Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG.
    N Engl J Med; 1985 Jun 20; 312(25):1600-3. PubMed ID: 4000198
    [Abstract] [Full Text] [Related]

  • 39. Complications of β-thalassemia intermedia in Iran during 1996-2010 (single-center study).
    Rafsanjani KA, Mafi N, Tafreshi RI.
    Pediatr Hematol Oncol; 2011 Sep 20; 28(6):497-508. PubMed ID: 21728720
    [Abstract] [Full Text] [Related]

  • 40. [German multicenter thalassemia study. Concept and initial results].
    Kohne E, Stahnke K, Kulozik AE, Kleihauer E.
    Klin Padiatr; 1992 Sep 20; 204(4):258-63. PubMed ID: 1518262
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.